

1 **Human airway ex vivo models: new tools to study the airway**
2 **epithelial cell response to SARS-CoV-2 infection**

3

4 Said Assou ^{1,#,*}, Engi Ahmed ^{1,2}, Lisa Morichon ^{1,3}, Amel Nasri ¹, Florent Foisset ¹, Carine
5 Bourdais ¹, Nathalie Gros ³, Sonia Wong ⁴, Aurelie Petit ², Isabelle Vachier ², Delphine
6 Muriaux ^{3,5}, Arnaud Bourdin ^{2,#,*}, John De Vos ^{1,6,#}

7

8 ¹ IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, F34295, France

9 ² Department of Respiratory Diseases, CHU Montpellier, Arnaud de Villeneuve Hospital,
10 INSERM, Montpellier 34000, France; PhyMedExp, University of Montpellier, INSERM
11 U1046, CNRS UMR 9214.

12 ³ CEMIPAI, Univ Montpellier, CNRS UAR3725, Montpellier, France.

13 ⁴ CEFE, Univ Montpellier, CNRS, EPHE, IRD, Montpellier, France

14 ⁵ IRIM, Univ Montpellier, CNRS UMR9004, Montpellier, France.

15 ⁶ Department of Cell and Tissue Engineering, Saint-Eloi Hospital, Montpellier, F34295
16 France.

17 # Co-senior authors.

18 **Short title:** SARS-CoV-2 signatures in *ex vivo* airway models

19 * **Corresponding authors:**

20 Said Assou, Institute for Research in Regenerative Medicine and Biotherapy, Hôpital Saint-
21 Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France. Fax: 33-(0) 4-67-33-
22 57-23. Email: said.assou@inserm.fr.

23 Arnaud Bourdin, Department of Respiratory Diseases, CHU Montpellier, Arnaud de
24 Villeneuve Hospital, 34000, Montpellier. France. Email: a-bourdin@chu-montpellier.fr

25 **Abstract**

26 Airway-liquid interface cultures of primary epithelial cells and of induced pluripotent stem
27 cell-derived airway epithelial cells (ALI and iALI, respectively) are physiologically relevant
28 models for respiratory virus infection studies because they can mimic the *in vivo* human
29 bronchial epithelium. Here, we investigated gene expression profiles in human airway
30 cultures (ALI and iALI models) infected or not with severe acute respiratory syndrome
31 coronavirus 2 (SARS-CoV-2) using publicly available and our own bulk and single-cell
32 transcriptome datasets. SARS-CoV-2 infection significantly increased the expression of
33 interferon-stimulated genes (*IFI44*, *IFIT1*, *IFIT3*, *IFI35*, *IRF9*, *MX1*, *OAS1*, *OAS3* and *ISG15*)
34 and inflammatory genes (*NFKBIA*, *CSF1*, *FOSL1*, *IL32* and *CXCL10*) at day 4 post-infection,
35 indicating activation of the interferon and immune responses to the virus. Extracellular matrix
36 genes (*ITGB6*, *ITGB1* and *GJAI*) also were altered in infected cells. Single-cell RNA
37 sequencing data revealed that SARS-CoV-2 infection damaged the respiratory epithelium,
38 particularly mature ciliated cells. The expression of genes encoding intercellular
39 communication and adhesion proteins also was deregulated, suggesting a mechanism to
40 promote shedding of infected epithelial cells. These data demonstrate that ALI/iALI models
41 help to understand the airway epithelium response to SARS-CoV-2 infection and are a key
42 tool for developing COVID-19 treatments.

43

44

45

46

47 **Introduction**

48 The rapid spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in
49 humans has posed a serious global health threat. Coronaviruses are part of a large family of
50 viruses that cause illnesses ranging from common colds to severe respiratory diseases,
51 including COVID-19 caused by SARS-CoV-2. SARS-CoV-2 is a single positive-stranded
52 RNA enveloped virus that replicates in epithelial cells [1]. Upon infection, SARS-CoV-2
53 binds the host ACE2 receptor through its spike protein, and enters the cells by fusion of the
54 viral membrane with the epithelial cell membrane or by endocytosis [2]. After binding, the
55 spike protein can be cleaved by TMPRSS2, a host membrane serine protease, facilitating viral
56 entry [1]. Then, the virus replicates inside epithelial cells and produces newly synthesized
57 viral particles that are secreted by the host cells [3].

58 Due to the COVID-19 long- and short-term effects on human health and the need to limit the
59 emergence of novel virus variants, significant efforts have been dedicated to understand the
60 viral infection mechanisms and to develop antiviral drugs using physiologically relevant *in*
61 *vitro* culture models that mimic *in vivo* phenotypes. Human airway epithelial cells in culture
62 are traditionally used for modeling respiratory diseases [4]. These cells can be obtained from
63 lung tissue biopsies and are cultured as primary airway epithelial cells in air-liquid interface
64 (ALI) systems that support epithelial cell differentiation and mimic key aspects of the
65 mucosal epithelium [5]. They can also be derived by differentiation of induced pluripotent
66 stem cells (iPSCs) in ALI systems (i.e. iALI) [6–9]. In both ALI and iALI systems, epithelial
67 cells are cultured on a permeable membrane with the medium in the basal chamber and the
68 epithelium exposed to air at the apical side of the membrane. In this system, cells are in
69 contact with air and can be induced to differentiate into a functional pseudo-stratified
70 epithelium. Several studies confirmed that ALI culture transcriptomic profiles are very similar
71 to those of *in vivo* airway epithelium obtained by bronchial brushing or biopsy [10,11]. ALI

72 and iALI models can be infected by viruses and have been used to model various mechanisms
73 of viral pathogenesis [12,13]. SARS-CoV-2 can replicate in both models [1,14] and infection
74 can be limited by interferon. This demonstrated interferon therapeutic potential for COVID-
75 19 treatments and the usefulness of these models as a high-throughput screening tool [15,16].
76 Additionally, ALI and iALI cultures from patients with respiratory diseases (e.g. chronic
77 obstructive pulmonary disease) recapitulate some of the *in vivo* disease characteristics, and are
78 used to assess the impact of smoke exposure on viral infection [12,17,18]. Therefore, ALI and
79 iALI cultures could help to understand SARS-CoV-2 effects in bronchial epithelium, by
80 analyzing the transcriptomic changes upon infection. ALI models are very helpful to identify
81 the key initiating steps of viral injury and innate epithelial cell defense that may or may not
82 lead to cell infection and replication. Increasing the number of models and of donors will
83 improve the robustness of the identified pathways by reducing the inter-individual
84 heterogeneity in viral susceptibility.

85 Various omic-based studies, including *in vivo* (human samples) and *in vitro* (model systems)
86 transcriptome profiling studies (bulk RNA sequencing), have highlighted the molecular
87 changes induced by SARS-CoV-2 infection [19–21]. The recent advent of single-cell RNA-
88 sequencing (scRNA-seq) provides a precious approach to carefully analyze gene expression
89 and cell composition. For instance, scRNA-seq has been used to identify the cells in the
90 human respiratory system with the highest expression of transmembrane receptors for SARS-
91 CoV-2 [22], and to show that in ALI cultures of nasal epithelial cells, ciliated and
92 goblet/secretory cells express progressively SARS-CoV-2 entry factors. Moreover, in infected
93 human bronchial epithelial-derived ALI cultures, scRNA-seq [23] revealed that ciliated cells
94 are a major SARS-CoV-2 target.

95 In the present study, we analyzed bulk and single-cell RNA-seq datasets to provide a detailed
96 picture of the gene expression changes in ALI and iALI models following SARS-CoV-2

97 infection. This analysis highlighted the molecular mechanisms involved in the induction of
98 the hyper-inflammatory state and innate immune response, including interferon signaling,
99 chemokines and extracellular matrix (ECM), and identified potential regulatory microRNAs
100 (miRNAs) for therapeutic interventions.

101 **Methods**

102 **ALI culture of primary airway epithelial cells and iPSC-derived airway epithelium for** 103 **scRNA-seq analysis**

104 Primary Human Bronchial Epithelial Cells (HBEC) were expanded and differentiated in ALI
105 culture following the protocol given by StemCell Technologies. Briefly, cells were
106 dissociated mechanically from bronchial biopsy specimens obtained by fiberoptic
107 bronchoscopy (approval number: 2013 11 05; NCT02354677) and cultured in PneumaCult-Ex
108 Plus expansion medium (cat #05041, StemCell Technologies, France) for 15 days. After the
109 expansion phase, differentiation was initiated by seeding 1.1×10^5 cells/insert on Transwell^R
110 polyester membranes (ref 3460, Corning, Kennebunk, United States). Once epithelial cells
111 reached confluence, the apical growth medium was removed, and the basal medium was
112 replaced by PneumaCultTM-ALI maintenance medium (cat #05002, StemCell Technologies,
113 France) (i.e. day 0 of ALI culture). Epithelial cells were allowed to differentiate at 37°C, 5%
114 CO₂ for 28 days.

115 iPSC-derived airway epithelium on ALI (iALI model) was generated as previously described
116 [6]. Briefly, the major stages of embryonic lung development were recapitulated as follows:
117 stage 1, definitive endoderm (day 0–3) using activin A; stage 2, anterior foregut endoderm
118 (day 4–8); stage 3, lung progenitor specification (day 9); and stage 4, epithelial layer (day 14).
119 After 40 days, the airway epithelium on iALI displayed morphologic and functional

120 similarities with primary human airway epithelial cells and included different airway cell
121 types (basal, secretory, and multi-ciliated cells).

122 **ScRNA-seq and data analysis**

123 Non-infected ALI and iALI cultures were dissociated with trypsin into single-cell
124 suspensions. Cell viability and aggregation were tested before starting the single-cell library
125 preparation. The concentration of freshly dissociated cells was adjusted to 1000 cells/ μ l in
126 HBSS/0.05% BSA and then the 10x Chromium Controller and the Chromium Single Cell 3'
127 Reagent kit V3.1 were used for performing the scRNAseq experiments. Library preparation
128 was performed according to the manufacturer's instructions using the Chromium Chip B
129 Single Cell kit, and Chromium Multiplex Kit (10X Genomics). Sequencing was performed in
130 paired-end mode with an S1 flow cell (28/8/87 cycles) and a NovaSeq 6000 sequencer
131 (Illumina) at the MGX core facility of Montpellier, France. First, the cell ranger mkfastq and
132 cellranger count pipelines were used for the initial quality control, sample demultiplexing,
133 mapping, and raw data quantification. Briefly, fastq files were run with the Count application
134 using default parameters and were aligned to the human genome reference sequence GRCh38,
135 filtered and counted. The C-loop software (version 6.2.0) was used to visualize clusters and
136 sub-clusters of transcriptionally related cells and to identify candidate genes the expression of
137 which was enriched in specific clusters. Clustering results were visualized with the t-
138 distributed Stochastic Neighbor Embedding (tSNE) technique. Bronchial cell
139 (biopsy/brushing samples) datasets included in [24] were analyzed through a COVID-19 Cell
140 Atlas website portal and were visualized using Uniform Manifold Approximation and
141 Projection (UMAP).

142 **Functional enrichment analysis of bulk RNA-seq datasets**

143 The unique bulk RNA-seq signature was obtained from a publicly available list of differential
144 expressed genes between primary human lung epithelium infected with SARS-CoV-2
145 (multiplicity of infection, MOI, = 2 for 24 h) and mock-treated controls [20]. The GO
146 functional enrichment and pathway enrichment analyses were performed with ShinyGO [26]
147 and Gene Set Enrichment Analysis (GSEA) (<http://www.broadinstitute.org/gsea/>). GO
148 annotations were divided in three categories: biological process, molecular function, and
149 cellular component. In the enrichment analysis, the Fisher' exact test was used to test whether
150 genes were enriched in a term, and an adjusted p value <0.05 was set as the screening
151 condition. The GenGo Metacore software was used to identify miRNA targets. Heatmaps and
152 gene networks were generated with Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood
153 City, CA, USA).

154 **Analysis of publicly available single-cell RNA-seq datasets**

155 A public scRNA-seq dataset (GEO accession number: GSE166766) of HBEC ALI culture
156 samples infected with SARS-CoV-2 (MOI ~ 0.01) was also analyzed [25]. The Velocity@
157 package was used to investigate the gene expression dynamics in the scRNA-seq data before
158 virus infection and at day 3 post-infection (dpi). RNA velocity quantifies the change in the
159 state of a cell over time by distinguishing unspliced and spliced mRNAs reads. To obtain de
160 counts of spliced and unspliced mRNAs reads, Velocity used the outputs of CellRanger
161 (version 3.0.2) alignments with the command line 'run10x' and the transcriptome
162 GRCh38.p12 (accession NCBI:GCA_000001405.27). At this step, loom files were created for
163 the input data of the scVelo tool [26]. This python package allowed normalizing with the
164 `scv.pp.normalize_per_cell()` function and transform `scv.pp.log1p()`. Genes were filtered by
165 keeping only the 2000 top highly variable genes (`n_top_genes = 2000` parameters for
166 `scv.pp.filter_and_normalize` function). Then, moments were calculated for each cell across its
167 nearest neighbors with `n_neighbors` set to 30 and the first 10 PCs using the `scv.pp.moments()`

168 function. Then, cell velocities were estimated using `scvelo.tl.velocity()` based on a stochastic
169 model of transcriptional dynamics. To visualize the velocity graph, data were projected on the
170 UMAP space and clusters defined by the CellRanger pipeline were colored. After cluster
171 identification on Seurat V4 [27], the function `cluster_analysis` from the SingleCellSignalR
172 package [28] was used to compute paracrine interactions between cell clusters and to predict
173 ligand–target links between interacting cells by combining their expression level with prior
174 knowledge on gene regulatory networks and signaling pathways. To compare ALI and iALI
175 samples, genes identified in our samples were combined with other publicly available datasets
176 that used infected iPSC-derived AT2 cells (iAT2) [16], specifically for the genes related to
177 inflammatory and interferon responses and extracellular ECM.

178 **SARS-CoV-2 virus stock and titration**

179 The hCoV-19/France/HDF-IPP11602i/2021 (21A - Delta – B.1.617.2) strain was supplied by
180 the National Reference Centre for Respiratory Viruses hosted by Institut Pasteur (Paris,
181 France). The human sample from which this strain was isolated was provided by Dr
182 Guiheneuf Raphaël, CH Simone Veil, Beauvais France. The strain was propagated in VeroE6
183 cells with DMEM containing 25mM HEPES at 37°C and 5% CO₂ and viruses were harvested
184 72 hours post-inoculation. Virus stocks were stored at -80°C. Viruses from infected cell
185 culture supernatants were titrated with the plaque assays on a monolayer of VeroE6 cells and
186 100µL of virus serial dilutions. The plaque forming unit (PFU) values were determined by
187 crystal violet staining and then by scoring the wells displaying cytopathic effects. The virus
188 titer was determined as the number of PFU/mL, and MOI was the PFU/cell ratio.

189 **Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)**

190 RNA was extracted from cells using the QIAshredder kit (QIAGEN, Redwood city, CA,
191 USA) and the RNeasy mini kit (Qiagen, Redwood city, CA, USA) according to the
192 manufacturer's instructions. Viral RNA was quantified by RT-qPCR in triplicate as described
193 [29], using the Luna Universal One-Step RT-qPCR Kit (New England Biolabs, Ipswich, MA,
194 USA) and a BIORAD CFX Opus 384 system. Relative gene expression was calculated for
195 each triplicate by normalizing to *GAPDH* level (control) and using the formula $2^{-\Delta Ct}$. Primers
196 are listed in Supplementary Table S1.

197 **Immunofluorescence analysis**

198 iALI cultures were fixed in 4% paraformaldehyde for 4 hours. After three PBS washes, iALI
199 samples were stored in PBS at 4°C. Samples were permeabilized in 0.5% Triton X-100/PBS
200 at room temperature for 20 min and then blocked with PBS/0.1% Triton X-100/1% bovine
201 serum albumin (BSA)/10% donkey serum at room temperature for at least 1h. Primary
202 antibodies against p63 (AF1916, Biotechne, Minneapolis, MN, USA), TubIV (T7941, Sigma,
203 Saint Louis, MO, USA) and SARS-CoV-2 M protein membrane (100-401-A55, Rockland
204 Immunochemicals, Pottstown, PA, USA) were diluted (1/100, 1/200 and 1/200, respectively)
205 in PBS/1%BSA/0.1%, Triton X-100 and added to the samples for overnight incubation. Then,
206 samples were washed three times with PBS/0.025% Triton X-100 before incubation (room
207 temperature for 2h) with the following secondary antibodies: anti-mouse coupled to
208 Alexafluor 555 (A31570, Invitrogen, Waltham, MA, USA), anti-rabbit coupled to Alexafluor
209 488 (A21206, Invitrogen, Waltham, MA, USA) and anti-goat coupled to Alexafluor 647
210 (A21447, Invitrogen, Waltham, MA, USA) (all diluted to 1/1000 in PBS/1% BSA/0.1%,
211 Triton X-100. After three washes in PBS/0.025% Triton X-100, samples were incubated with
212 DAPI (D9542, Sigma, Saint Louis, MO, USA), diluted 1/2500 in PBS, for 5 min and rinsed in
213 PBS. Then, iALI samples were separated for their support and mounted between glass slides.

214 Confocal images were acquired using a Cell-Discoverer 7 LSM900 confocal laser-scanning
215 microscope (Zeiss, Germany) at 40x magnification, and processed with Zen Blue.

216 **Statistical analysis**

217 Data are presented as the mean \pm SEM, unless otherwise specified. Statistical analyses were
218 performed with the GraphPad Prism 5 software (Student's *t*-test; GraphPad). The shown data
219 were from representative experiments, with similar results in at least three independent
220 biological replicates, unless otherwise specified. Differences were evaluated using the
221 Student's *t*-test. A *p* value ≤ 0.05 was considered significant.

222 **Results**

223 **Cellular landscapes of non-infected human lung epithelium models**

224 One of the challenges in COVID-19 research is the need of physiologically relevant *in*
225 *vitro* cell culture models to mimic the native environment. To this aim, non-infected HBEC in
226 ALI culture and iPSC-derived epithelial-like cells in iALI culture were analyzed by scRNA-
227 seq to generate a comprehensive repertoire of the cell populations present in these models.
228 Single-cell transcriptome data were obtained also from lung epithelium collected by bronchial
229 biopsy or brushing (Figure 1A). Analysis of these scRNA-seq data from these three models
230 (biopsy/brushing bronchial cells, ALI, and iALI cultures) (Figure 1B) showed that most
231 epithelial cell markers, such as *SCGB1A1/CC10* (secretoglobin family 1A member 1;
232 secretory cells), *TP63* (tumor protein p63; basal cells), and *FOXJ1* (forkhead box J1; multi-
233 ciliated cells) were present in the three sample types. This suggested that non-infected ALI
234 and iALI models contain the essential cell types necessary for bronchial epithelium function
235 and can be used as experimental *ex vivo* models to study SARS-CoV-2 infectivity.
236 Comparison of the single-cell landscapes indicated that unlike the biopsy/brushing and ALI

237 models, the iALI model expressed *ASCLI*, a marker of neuroendocrine cells, but not *FOXII*
238 (ionocyte marker) and all models express *POU2F3* (tuft cell marker). In addition, immune
239 cells were an important cell fraction in biopsy/brushing samples (Figure 1C), but were absent
240 in the ALI and iALI models. This major difference may help to (i) understand the epithelial-
241 intrinsic innate inflammatory response to SARS-CoV-2 infection; (ii) identify the key
242 epithelial target cells; and (iii) compare the molecular mechanisms triggered in the absence
243 (iALI and ALI) and the presence (biopsy–brushing samples) of immune cells.

244

245 **Cell-specific expression of single-stranded RNA virus receptors in non-infected human** 246 **lung epithelium models**

247 The expression of receptors to which single-stranded RNA (ssRNA) viruses can bind is a key
248 factor for virus infection and transmission. Analysis of scRNA-seq data from the three non-
249 infected lung epithelium models showed that *CDHR3* (encoding cadherin related family
250 member 3, the entry receptor for rhino-virus C) [30] was specifically expressed in ciliated
251 cells, and *CD55* (Coxsackie-virus B1 receptor) [30] in secretory cells (Figure 1D). *ACE2*
252 (SARS-CoV-2 receptor) was expressed by ciliated, secretory and basal cells. Moreover, in
253 biopsy/brushing samples, *ACE2*⁺ cells were overrepresented among all epithelial cell types
254 compared with immune cells, including macrophage, endothelial and dendritic cells (Figure
255 1D). This is in line with a recent study reporting the absence of viral transcripts in
256 bronchoalveolar fluid and peripheral blood mononuclear cell samples collected from patients
257 with COVID-19 [31]. Collectively, scRNA-seq data analysis of the three cell culture models
258 showed expression of ssRNA virus receptors in secretory, ciliated and basal cells, suggesting
259 the possibility of modeling ssRNA virus infection, including SARS-CoV-2, in airway
260 epithelium *in vitro*.

261

262 **Changes induced by SARS-CoV-2 infection in the ALI model**

263 A recent bulk RNA-seq dataset [20] was used to compare the gene expression profiles of
264 infected and non-infected human bronchial epithelium in order to identify the “SARS-CoV-2
265 bulk RNA-seq signature” induced by SARS-CoV-2 infection in the ALI model
266 (Supplementary Table S2). GO biological process and molecular function analyses of this
267 “SARS-CoV-2 bulk RNA-seq signature” showed significant overexpression of genes
268 implicated in immune response, cytokines and chemokine activity (Figure 2A). The GO
269 cellular component enrichment analysis showed that many differentially expressed genes
270 were related to ECM and ECM regulators (Figure 2A). GSEA confirmed the significant
271 upregulation of the interferon and inflammatory pathways (Figure 2B). Heatmaps revealed
272 that the core transcriptional response included genes implicated in “immune cell trafficking”,
273 “inflammatory response”, “cellular movement”, “inflammatory response” and “cell-to-cell
274 signaling and interaction” (Figure 2C), which is consistent with the biological processes and
275 molecular functions highlighted above. The top categories, ranked in accordance with their
276 $-\log(\text{P-value})$, are shown in Supplementary Table S3. In total, 146 enriched canonical
277 pathways were identified (Supplementary Table S4). The interferon signaling pathway was
278 ranked first with a $-\log(\text{P-value})$ of 14.1. Many genes belonging to the interferon machinery
279 implicated in the antiviral response and viral replication were identified (Figure 2D), such as
280 interferon-induced genes (*IFI27*, *IFI35*, *IFI44*, *IFI44L*, *IFIH1*, *IFIT1*, *IFIT3*, *IFITM1*,
281 *IFITM3*), interferon regulatory factors (*IRF7* and *IRF9*), interferon-stimulated genes (*ISG15*
282 and *ISG20*), MX dynamin-like GTPases (*MX1* and *MX2*), oligoadenylate synthetases (*OAS1*,
283 *OAS2* and *OAS3*) and the master suppressor of cytokine signaling (*SOCS3*). With a Z-score
284 >2 as a threshold of significant activation, the following signaling pathways were identified as
285 activated: '*IL17* signaling' (Z-score=5.099), '*HMGB1* signaling' (Z-score=4), '*TREMI*
286 signaling' (Z-score=3.742), 'Toll-like Receptor signaling' (Z-score=2.53), '*IL-8* signaling' (Z-

287 score=4.123), 'iNOS signaling' (Z-score=3.162), 'IL-6 signaling' (Z-score=3.37), 'TNFR1
288 signaling' (Z-score=2.121), 'IL-1 signaling' (Z-score=3) and 'PI3K/AKT signaling' (Z-
289 score=2.333). Conversely, some of the enriched signaling pathways had Z-scores lower than -
290 2, such as 'inhibition of matrix metalloproteases' (Z-score=-2), 'PPAR signaling' (Z-score=-
291 3.606) and 'erythropoietin signaling pathway' (Z-score=-2.524). Concerning upstream
292 regulators (Supplementary Figure S1, Supplementary Table S5), the highest ranked regulatory
293 effects with consistency scores up to 4.8 strongly suggested that the upstream regulators *TNF*,
294 *IL1A* and *F2* may be responsible for the gene expression changes in the SARS-CoV-2 bulk
295 RNA-seq signature. IPA analysis predicted that these upstream regulators are involved in
296 chemotaxis, invasion and cell movement, mainly through induction of their targets, including
297 many genes associated with the innate immune response (*IL1B*, *NFKBIA*, *CXCL1*, *NOD2*,
298 *PLAUR*, *C3*, *ITGB2*, *S100A8*, *PLAU*, *S100A9*, *IL1A*, *TNF*), cytokine and chemokine activities
299 (*CCL20*, *CXCL2*, *CXCL3*, *CXCL5*, *CXCL6*, *CXCL8*, *CXCL10*, *IL6*, *IL8*, *IL32*, *IL33*, *CSF3*,
300 *CSF2*, *CSF1*), and genes implicated in ECM degradation, such as matrix metalloproteases
301 (*MMP13*, *MMP9*, *MMP1*). These metalloproteases are connected to pro-inflammatory
302 chemokines and play an operative role in ECM degradation during inflammation that can be
303 triggered by virus infection. Our data highlighted and confirmed that matrix
304 metalloproteinases play key roles in viral infection and its progression [32] through airway
305 remodeling (i.e. loss of the epithelium barrier integrity [33] and elastin degradation in the
306 ECM [34]).

307

308 **Conserved expression of the epithelial cell response to SARS-CoV-2 infection in the iALI** 309 **model**

310 Then, bulk RNA sequencing datasets of iPSC-derived alveolar epithelial type 2-like cells
311 (iAT2) infected by SARS-CoV-2 and mock-infected [16] at 1 and 4 dpi were analyzed to

312 determine whether the SARS-CoV-2 bulk RNA-seq signature observed in the ALI model was
313 present also in the iALI model. Analysis of the temporal distribution of RNA-seq reads
314 allowed identifying four major gene groups (Figure 3A): (a) genes that were upregulated early
315 (at 1 dpi) and the expression of which gradually increased from 1 to 4 dpi (*NFKBIA*, *CSF1*,
316 *IL32* and *FOSL1*); (b) genes that were upregulated early and the expression of which was not
317 changed at 4 dpi (*IL23A*, *CXCL10*, *CXCL20* and *PLAUR*); (c) genes that were upregulated at
318 1 dpi and were then downregulated at 4 dpi (*CXCL3*, *CXCL5*, *CXCL1* and *LOX*); and (d)
319 genes that were upregulated only at 4 dpi (*MMP9* and *MMP13*). In addition, and like in the
320 ALI model, in the COVID-19 iALI model, the interferon response was activated, as indicated
321 by the upregulation of genes encoding interferon induced proteins and interferon regulatory
322 factors (Figure 3B). This suggests that the ALI and iALI models share common interferon
323 response regulation features. Conversely, the expression kinetics of ECM-related genes
324 showed that some genes (*ITGB6*, *ITGB1*, *GJAI*, *VIM* and the ECM regulator *PLOD2*, which
325 encode proteins of the host cell cytoskeleton structure) were progressively downregulated
326 during SARS-CoV-2 infection in the iALI model (Figure 3C). This indicated that the ECM
327 and adhesion pathways are affected during cell-to-cell SARS-CoV-2 transmission. Moreover,
328 the expression of *EpCAM* (epithelial cell adhesion molecule), an epithelial cell surface
329 marker, progressively decreased, and that of the stromal cell marker *COL1A1* progressively
330 increased (Figure 3D), suggesting epithelial mesenchymal transition.

331

332 **Experimental validation of the epithelial cell response to SARS-CoV-2 infection in the** 333 **iALI model**

334 To gain insight into the molecular basis of SARS-CoV-2 infection in the iALI model, iALI
335 bronchial epithelium was exposed to SARS-CoV-2 Delta at low MOI (0.05) to let the
336 infection take hold for 4 days and then the expression of interferon-induced genes and

337 regulatory factors, viral entry genes and ECM genes was investigated. Viral DNA
338 quantification confirmed infection of iALI cultures. The virus was detected at the apical side
339 at 1 dpi and also at 4 dpi (Figure 4A). Moreover, SARS-CoV-2 membrane protein colocalized
340 with tubulin α 4a (TubIV), suggesting preferential infection of ciliated cells (Figure 4B). RT-
341 qPCR analysis of infected cells showed activation of the interferon signaling pathways at 1
342 dpi and 4 dpi. Interferon-induced proteins (*IFI44*, *IFIT1*, *IFIT3*, *IFI35*), interferon regulatory
343 factors (*IRF9*, *MX1*, *ISG15*), oligoadenylate synthetases (*OAS1*, *OAS3*) and chemokine ligand
344 (*CXCL10*) were upregulated at 4 dpi (Figure 4C). Conversely, viral infection did not alter the
345 expression of genes encoding adhesion molecules, such as *GJAI* and *ITGB1*, unlike what
346 observed upon infection at higher MOI (0.5) (Figure 3C). In agreement with this observation,
347 trans-barrier electrical resistance (TEER) of iPSC-derived epithelial cells was comparable in
348 non-infected and infected (at low MOI = 0.05) iALI cultures from 1 to 4 dpi, indicating that at
349 this infection level, epithelium integrity was not disrupted (Figure 4D). Altogether, these data
350 show that the iALI model is a faithful and sensitive model for SARS-CoV-2 infection.

351

352 **Epithelial cell communication networks in response to SARS-CoV2 infection**

353 ALI cultures include different cell types connected by tight and adherens junctions.
354 Communication between epithelial cells occurs through the release of a variety of small
355 molecules, including cytokines and chemokines. To investigate the impact of SARS-CoV2
356 infection on ligand/receptor interaction between the different airway cell types, scRNA-seq
357 data from HBEC ALI cultures infected or not with SARS-CoV-2 (MOI 0.01) were analyzed
358 using the SingleCellSignalR method. Comparison of the summary chord diagram indicated a
359 decrease in the number of paracrine interactions between the main epithelial cell types after
360 2dpi (Figure 5A), which strongly suggests an impact of SARS-CoV2 infection on intercellular
361 communications. For instance, expression of receptor tyrosine kinase (*RET*) and its ligand

362 artemin (*ARTN*), one of the most preeminent interacting pair between neuroendocrine cells
363 and other epithelial cells, was strongly decreased at 3 dpi (Figure 5B). This suggests that
364 neuroendocrine cells are particularly sensitive to environmental stimuli (e.g., viral infection),
365 and act as a rheostat to orchestrate ALI-culture responses.

366

367 **RNA velocity reveals discrepancies between non-infected and infected epithelium in the** 368 **ALI model**

369 To further characterize the ALI model transcriptional dynamics in response to virus infection,
370 the single-cell RNA velocity was measured in SARS-CoV-2 infected and non-infected
371 epithelial ALI cultures using a dynamic model of transcriptional state based on unspliced and
372 spliced transcript counts [26]. Cell trajectory analysis revealed that non-infected ALI
373 epithelial cells displayed two distinct bifurcation points through two different epithelial
374 transition states. The first bifurcation point included basal cells (*TP63*⁻/*KRT5*⁺) that directly
375 differentiate into ciliated cells, and the second bifurcation point mainly included basal cells
376 (*TP63*⁺/*KRT5*⁺) that preferentially differentiate into secretory cells and then into ciliated
377 cells. This placed secretory cells in an intermediate position between basal cells and mature
378 ciliated cells (*DNAH9*⁺) (Figure 5C). Velocity ordering analysis in infected cells revealed a
379 change in the ciliated cell differentiation trajectory. Indeed, basal cells were all oriented to
380 differentiate into ciliated cells through a secretory cell state. Moreover, *DNAH9*⁺ infected cell
381 mapping within ALI epithelial cells revealed that ciliated cells were more susceptible to
382 infection compared with other cell types, like *DNAH9*⁺ mature ciliated cells that are
383 preferentially eliminated during SARS-CoV-2 infection (Figure 5D). Collectively, the
384 dynamic ALI airway model provides a useful tool for *in vitro* studies on SARS-CoV-2/other
385 virus infection and antiviral testing.

386

387 **Potential miRNA regulators of the epithelial cell intrinsic response to SARS-CoV-2**
388 **infection**

389 The GenGo Metacore software was then used to identify miRNAs that regulate the epithelial
390 cell response genes after SARS-CoV-2 infection in the ALI and iALI models (i.e. potential
391 antiviral targets). This analysis identified 167 miRNAs that regulate the key epithelial cell
392 intrinsic genes deregulated upon viral infection (Figures 3A-B). Among these miRNAs, 44
393 were regulators of interferon response genes and 123 regulated inflammatory response genes
394 (complete list of miRNAs in Supplementary Table S6). More than 54% of the interferon gene
395 targets were regulated by more than one miRNA. For instance, *SOCS3* and *MX2* were
396 targeted by 24 and 5 miRNAs, respectively (Figure 6A). The inflammatory genes regulated by
397 the highest number of miRNAs were *MMP9* ($n = 29$ miRNAs), *NFKBIA* ($n = 19$), *MMP13*
398 ($n = 19$), *CSF1* ($n = 12$), *FOSL1* ($n = 11$) and *LOX* ($n = 11$) (Figure 6B). *MIR34a* was
399 identified as a potential regulator of *MMP9*, *NFKBIA*, *FOSL1*, *CXCL10*, whereas *MIR203* and
400 *MIR19* were common regulators of *NFKBIA*, *MMP13*, *SOCS3*. *MIR138-5p* and *MIR-326-3p*
401 are validated regulators of *ISG15* and *ISG20*. *MIR650*, *MIR541-3p* and *MIR302d-3p* regulated
402 several interferon- γ stimulated genes, including *MX1*, *MX2*, *IRF7* and *IRF9*. *CSF1* and *LOX*
403 were targets of *MIR130a* and *MIR29*, respectively. These miRNAs can attenuate the
404 inflammatory response and inhibit key coagulation cascade factors, thus preventing
405 inflammatory epithelium damage. Therefore, they are potential miRNA-based therapeutics
406 against COVID-19.

407 **Discussion**

408 The human airways are lined by an epithelium with three abundant specialized cell types
409 (basal, secretory, and multi-ciliated cells) and some rare cell types (neuroendocrine cells, tuft
410 cells and ionocytes) [35–37], on a stroma composed of mesenchymal cells, smooth muscle

411 cells and immune cells [38]. Primary HBECs cultured in ALI conditions can be used to study
412 airways *in vitro*. More recently, our group and others have generated functional airway
413 epithelium from human iPSCs (iALI models) with a marked similarity to the airway
414 epithelium *in vivo* [6,8,39–41]. As expected, scRNA-seq analysis of ALI and iALI models
415 showed that immune cells, which are found in biopsy/brushing-derived primary cultures, were
416 absent in these models. Conversely, the stromal component was exclusively found in ALI and
417 iALI models, suggesting a role in the epithelium maintenance. Of note, neuroendocrine cells
418 were mostly identified in the iALI model, compared with the ALI model. Our analysis
419 characterized rare cell types, such as ionocytes, that strongly express *FOXI1* and *ASCL3*
420 [36,42].

421 SARS-CoV-2 infection in ALI and iALI models induces virus-linked epithelial disruption,
422 loss of mature ciliated cells, and triggers intrinsic immune responses. Despite the differences
423 in terms of cell composition, the ALI and iALI models exhibit relevant proportions of airway
424 cell types, express virus receptors (ACE2, CDHR3, CD55), and have been used to model
425 various mechanisms of SARS-CoV-2 pathogenesis [43]. These models provide a suitable and
426 reliable platform for researchers to study SARS-CoV-2 pathogenesis during infection.

427 In this study we analyzed the bulk and single-cell transcriptomes of ALI and iALI cultures
428 infected with SARS-CoV-2. This highlighted the emergence of pro-inflammatory and
429 interferon signatures in which epithelial cells activated the expression of several cytokines,
430 chemokines, interferon, and downregulated ECM-related genes in response to SARS-CoV-2
431 at different times after infection. Most of these genes play essential roles in virus control and
432 also in disease development. For instance, many chemokines (*CCL2*, *CCL3*, *CCL20*, *CXCL1*,
433 *CXCL3*, *CXCL10*, *IL-8*) associated with inflammatory responses were expressed in the ALI
434 and iALI models. *CCL2*, *CXCL10* (called *IP-10*) and *IL-8* are associated with airway
435 inflammation, and high serum levels of these chemokines were found in patients with severe

436 SARS [44]. *CCL3* also is involved in viral infections [45]. Our detailed analysis of the
437 transcriptional response to SARS-CoV-2 infection showed that ALI and iALI cultures
438 produced an unbalanced cytokine response, with preferential upregulation of genes encoding
439 cytokines (for instance *IL-6*, *IL-1 β* and *IL-33*) that are mainly implicated in the defense
440 against extracellular aggression. Several studies showed that IL-6 serum levels are increased
441 in patients with COVID-19 [46]. IL-6 is involved in acute inflammation due to its implication
442 in controlling the acute phase response [47]. IL-6 production is increased by TNF- α and IL-
443 1 β [48]. In animal models of SARS-CoV-infection, TNF activity neutralization provides
444 protection against SARS-CoV morbidity and mortality [49]. A large number of data showed
445 the role of interferons in SARS-CoV2 infection. Interferons exercise their biological functions
446 by regulating the expression of interferon-stimulated genes (ISGs). ISG upregulation has been
447 described in various cells from patients with severe COVID-19 [50,51]. Here, we found that
448 infection with SARS-CoV-2 induced a strong interferon response in ALI and iALI cultures,
449 marked by high expression of *ISG15* (key factor in the innate immune response to SARS-
450 CoV-2 infection), *ISG20* (with antiviral activity against RNA viruses), *IRF-7* (the master
451 regulator of interferon responses) [52], and of several ISGs (*IFITM1*, *IFITM3*, *IRF9*, *IFI27*,
452 *OAS2*, *MX1*, *MX2*, *SOCS3*) involved in the regulation of the host defense responses to the
453 virus [53]. This suggests that *in vitro*, ALI/iALI epithelium can develop an intrinsic response
454 to SARS-CoV-2 infection focused on the activation of the interferon pathways. This is in line
455 with a study showing strong expression of many ISGs in the respiratory tract of patients with
456 COVID-19, supporting the idea that interferon-mediated immune response plays a key role in
457 SARS-CoV-2 infection control [51].

458 Although SARS-CoV-2 pathogenesis has not been fully understood, it seems that excessive
459 immune responses play a key role. Evidence suggests that immune response deregulation
460 causes lung damage [54]. Here we found that in infected ALI and iALI cultures, chemokines

461 and cytokines, including IL-6, IL-1 β , interferon and TNF, were upregulated to coordinate all
462 aspects of the immunogenic response to SARS-CoV-2 infection. Additionally, SARS CoV2-
463 related pneumonia with severe respiratory failure is characterized by enhanced ECM [55].
464 Similarly, in infected ALI cultures, cells expressing *MMP9*, an enzyme that participate in
465 ECM remodeling, were markedly increased. The molecular pathways involved in *MMP-9*
466 regulation during SARS-CoV2 infection are not known. Ueland et al. suggested that *MMP-9*
467 may be an early indicator of respiratory failure in patients with COVID-19 [56], and Hsu et al.
468 reported an important increase of MMP-9 concentration in the plasma of patients who
469 developed acute respiratory distress syndrome [57]. Conversely, in infected ALI cultures,
470 cells expressing ECM-related genes (e.g. *VIM*, *ITGB1*, *ITGB6*, *GJA1* and *PLOD2*) were
471 decreased compared with control cultures. Vimentin and integrin are critical targets for
472 SARS-CoV-2 host cell invasion [58,59]. Identifying the molecular mechanisms that lead to
473 their regulation will be pivotal to understand their role in epithelium damage and reparation
474 during SARS CoV2 infection.

475 Another important question we addressed concerned the miRNA role in the regulation of
476 genes deregulated in infected ALI/iALI cultures. Recent investigations revealed that miRNAs
477 are implicated in viral pathogenesis by altering the miRNA-modulated host gene regulation or
478 the host immune system [60]. The variation of miRNA levels during virus infection and their
479 role in modulating SARS-CoV-2 infection in human cells have been well described [17].
480 Thus, miRNA-antagonists or -mimics could be used to develop new therapeutic strategies for
481 the treatment of patients with COVID-19 [61]. The anti-viral response by miRNAs may
482 implicate the regulation of their mRNA targets that participate in the cellular response to viral
483 infection. Interferon signaling was one of the primary effectors against SARS-CoV2
484 infections in both ALI and iALI models. Moreover, genes encoding members of this pathway
485 are direct targets of many miRNAs. For instance, *MIR138* regulates *ISG15* expression by

486 direct binding to its 3' untranslated region (UTR) [62]. Similarly, *MIR326-3p* reduces the
487 activity of an *ISG20* 3' UTR luciferase reporter [63]. *MIR650*, *MIR29a-3p* and *MIR130a-3p*
488 regulate other ISGs, such as *MX1*, *MX2*, *IFITM3* and *IFITM1* [64–66]. Moreover, many
489 miRNAs target the 3'UTR site of matrix metalloprotease-encoding genes. For instance,
490 *MIR34a* and *MIR19* target *NFKBIA* [67] (critical for SARS-CoV-2 entry in the cells) and
491 *MMP9* [68] (macrophage-derived biomarker associated with inflammation), whereas
492 *MIR130a* targets the 3'UTR of pro-inflammatory metabolite genes (e.g. *LOX* [69] that
493 interacts with SARS-CoV-2) [70]. Altogether, different culture models are necessary to
494 validate the biological effect of these candidate miRNAs to SARS-CoV-2 infection and to
495 understand the interactions between host ISGs, cytokines and miRNAs. More investigations
496 are needed to determine the expression profiles of key miRNAs during viral infection, to
497 better predict disease severity, and to develop new therapeutic options based on these
498 miRNAs for COVID-19 treatment and/or prevention.

499 **Conclusions**

500 Here, we characterized of two ALI and iALI airway models to understand SARS-CoV-2
501 infection pathogenesis. We identified the inflammatory and interferon profiles induced in
502 these models in response to SARS-CoV-2 infection. Understanding the long COVID19
503 effects remains a challenge and will require also these models.

504

505 **Funding**

506 Supported by grants from the University Hospital of Montpellier (Appel d'offre interne, projet
507 CILIPS 9174, projet INVECCO), the association Vaincre la Mucoviscidose (Grant
508 #RIF20170502048), the Fondation pour la Recherche Médicale (Grant #FDM20170638083),

509 the Labex Numev (ANR-10-LAB-20), and Astrazenca. The acquisition of the Cell-Discoverer
510 7 LSM900 microscope was funded by FEDER-FSE Région Occitanie throughout the MIP-
511 FISH project. Part of this research project was supported by the CNRS INSB funding through
512 the VIROCRIB program.

513 **Author contributions**

514 Conceptualization and supervision: S.A., A.B and J.D.V.; Resources, A.B., J.D.V.; Data
515 analysis and interpretation: S.A., A.B, A.N., S.W., N.G., D.M., A.B., J.D.V; Collection and/or
516 assembly of data: S.A., E.A, F.F., C.B., A.P., I.V., D.M., A.B., J.D.V; Validation, L.M., N.G.,
517 D.M.; Writing – Original Draft, S.A, A.B, J.D.V.; Writing – Review & Editing, S.A., E.A,
518 L.M., D.M., A.B., J.D.V.. Scientific and technical support: all authors listed have made a
519 substantial, direct, intellectual contribution to the work, reviewed the final manuscript, and
520 approved it for publication

521 **Ethics declarations**

522 **Ethics approval and consent to participate**

523 Subjects were recruited at Arnaud de Villeneuve hospital, Montpellier, France, under study
524 protocols approved by the ethics committee - RRR study, NCT02354677, 2013-A01405-40
525 and INVECCO study, NCT03181204, 2017-A00252-51. All patients have been informed and
526 agreed to participate by signing written consent forms.

527 **Conflict of interest**

528 A.B. reports grants, personal fees, non-financial support and other from AstraZeneca; J.D.V.
529 reports personal fees and other from Stem Genomics, personal fees and other from MedXCell
530 Science, personal fees from Gilead, personal fees from Celgene, outside the submitted work.
531 In addition, J.D.V. and S.A. have a pending patent EP20150306389. S.A. reports personal

532 fees and other from Stem Genomics, outside the submitted work. E.A, L.M., A.N., F.F., C.B.,
533 S.W., A.P., I.V., D.M., declare no conflict of interest.

534 **Data set availability**

535 Publicly available data were obtained from GEO datasets: GSE147507 and GSE166766.
536 Interactive exploration tools: <https://www.covid19cellatlas.org/index.healthy.html> and
537 https://cellxgene.cziscience.com/d/cellular_census_of_human_lungs_bronchi-17.cxg/. The
538 gene expression profile from publicly RNA-seq data can be browsed with an interactive web-
539 tool at: <https://crem.shinyapps.io/iAEC2infection/> (GSE153277).

540

541 **Figures**

542 **Figure 1: Distribution of the different airway epithelial cell types the three lung tissue**
543 **models.** (A) Schematic representation of the scRNA-seq experimental workflow: airway
544 epithelium sources (biopsy/brushing-derived cells, ALI culture of primary bronchial epithelial
545 cells and iALI culture of iPSC-derived epithelial-like cells), generation of scRNA-seq
546 libraries and sequencing, computational analysis to identify cell types. The brushing/biopsy
547 epithelium scRNA-seq data were from [24]. The ALI and iALI scRNA-seq data were
548 generated in our laboratory (see Methods). (B) Contribution of each cell type in the three
549 models. UMAP and tSNE were used to show the contribution of *SCGB1A1*⁺, *TP63*⁺,
550 *FOXJ1*⁺, *FOXI1*, *POU2F3*⁺, and *ASCL1*⁺ cells (dark gray). (C) UMAP projection of the
551 different cell types. The feature plots display the subset of airway epithelial cells obtained
552 from biopsy/brushing of healthy donors [24]. (D) Maps of the expression of ssRNA virus
553 receptors in single cells from the three models. UMAP and tSNE were used to show the cell
554 types that express the ACE2, CDHR3 and CD55 receptors.

555

556 **Figure 2: Analysis of GO terms enriched in the unique bulk RNA-seq signature of the**
557 **ALI model upon SARS-CoV-2 infection.** (A) Pathway enrichment analyses were performed
558 with human gene names. The size of the blue dots corresponds to the enrichment (FDR) and
559 bigger dots indicate more significant *p*-values. The biological process, molecular function,
560 and cellular component categories revealed the high enrichment of immune response and
561 cytokine/chemokine activities upon SARS-CoV-2 infection. (B) GSEA performed using the
562 unique bulk RNA-seq signature upon SARS-CoV-2 infection. The heat map shows the
563 (clustered) genes in the leading-edge subsets and the dynamic expression of genes involved in
564 immune response, interferon response, defense response, TNF-signaling and response to
565 cytokines. (C) Enrichment heat map (IPA) showing the dynamic activity of canonical
566 pathways after SARS-CoV-2 infection. Each colored rectangle is a biological function and the
567 color range indicates its activation state (orange for an activated pathway with Z-score > 2,
568 and blue for an inhibited pathway with Z-score <-2). The pathways were classified into
569 different types according to the IPA database. (D) The network shows the interactions of
570 interferon (IFN)-stimulated genes. Nodes shaded in pink represent protein-coding genes that
571 are upregulated in the ALI model upon SARS-CoV-2 infection. Labels in nodes and edges
572 (lines) illustrate the nature of the relationship between genes and their functions. A dotted line
573 represents an indirect interaction and a solid line a direct interaction. IPA, Ingenuity Pathway
574 Analysis. GO, Gene Ontology.

575

576 **Figure 3: Dynamic gene expression changes in the iALI model upon SARS-CoV-2**
577 **infection.** Expression levels of (A) inflammatory cytokines/chemokines, including (a) genes
578 that were upregulated early and the expression of which gradually increased upon SARS-
579 CoV-2 infection, from 1 to 4 dpi; (b) genes that were upregulated early and the expression of

580 which remained constant between 1 and 4 dpi; (c) genes that were upregulated specifically at
581 1 dpi and were then downregulated at 4 dpi; and (d) genes that became upregulated at 4 dpi.
582 Expression of genes implicated in the (B) interferon response, (C) extracellular matrix, and
583 (D) epithelial/stromal gene upon. Normalized expression levels (counts per million reads)
584 were quantified by RNA-seq using data from [16] (human iPSC-derived AT2 cells infected or
585 not with SARS-CoV-2).

586

587 **Figure 4: Validation of SARS-CoV-2 infection in the iALI model.** (A) iALI cultures were
588 infected with SARS-CoV-2 Delta (MOI=0.05) and viral RNA was quantified by RT-qPCR
589 (gene E/mL). iALI cultures were washed by adding culture medium at the apical side at 37°C
590 for 15 min, then viral RNA was extracted and quantified in triplicate by RT-qPCR
591 (amplification of the viral envelope gene). Data are from three independent experiment (a, b,
592 c) using three different iALI cultures. The standard deviation shows the result variability. (B)
593 iALI cultures were stained with anti-SARS-CoV-2 M protein (viral membrane, green), anti- α -
594 tubulin (ciliated cell marker, orange) and anti-P63 (basal cell marker, red) antibodies. Nuclei
595 were counterstained with DAPI (blue). SARS-CoV-2 was identified on the motile cilia. Scale
596 bar: 20 μ m. (C) RT-qPCR analysis of the expression of genes encoding inflammatory and
597 interferon-related factors in iALI cultures infected with SARS-CoV-2 (MOI 0.05) at 1 dpi and
598 4 dpi. Data are the mean \pm SEM of three independent experiments with three technical
599 replicates/each (9 samples); *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001, ns: not significant
600 (Student's *t* test). (D) Transepithelial resistance was measured daily with an EVOM2 (WPI,
601 Friedberg, Germany), while the apical side was submerged with culture medium.
602 Measurement were done after 10 min of incubation at 37°C. MOI: multiplicity of cellular
603 infection.

604

605 **Figure 5: Paracrine interactions and single-cell trajectories in SARS-CoV-2-infected**
606 **ALI cultures.** (A) Circos plot showing potential interactions (ligands-receptors) made by
607 various epithelial cell types in non-infected (Mock) and SARS-CoV-2-infected ALI cultures
608 at 1, 2, and 3 dpi. The smallest number of paracrine interactions was observed in infected
609 cultures at 2 and 3 dpi. Arrows point to the receptors. (B) Violin plots showing the expression
610 of the ligand *ARTN* and its receptor *RET* in the various airway cell types identified by scRNA-
611 seq before (CTR) and after SARS-CoV-2 infection (1 and 3 dpi). (C) The velocity field
612 revealed two distinct tracks used by basal cells to form ciliated cells in non-infected ALI
613 cultures (mock), but not in SARS-CoV-2-infected cultures (2 dpi). (D) Left, gene expression
614 of known markers of premature (*FOXJ1*⁺) and mature ciliated cells (*DNAH9*⁺) is visualized
615 on the t-SNE plot in the mock sample. Right, the t-SNE plot shows the absence of mature
616 ciliated cells (*DNAH9*⁺) at 2 dpi.

617 **Figure 6: Identification of miRNA targets as potential COVID-19 therapeutics.**
618 Schematic representation of potential miRNAs that target some genes implicated in the
619 interferon and inflammatory responses upon SARS-CoV-2 infection of ALI cultures. Only the
620 miRNAs experimentally validated are represented. In the figure change into: Number of
621 miRNAs targeting a gene.

622

623 **Supplementary Tables**

624 **Table S1:** Primer pairs used for validation by RT-qPCR

625 **Table S2:** List of the 515 genes specific to the SARS-CoV-2 bulk RNA-seq signature
626 (transcriptome analysis by Blanco-Melo, D et al. [20]).

627 **Table S3:** List of the top GO categories identified by Ingenuity Pathway Analysis using the
628 515 genes listed in Table S2.

629 **Table S4:** List of the 146 enriched canonical pathways identified in the SARS-CoV-2 bulk
630 RNA-seq signature.

631 **Table S5:** Lists of genes targeted by the upstream regulator's *TNF*, *IL1A* and *F2* identified
632 using IPA Upstream Regulator Analysis.

633 **Table S6:** Exhaustive lists of miRNAs that are putative regulators of genes implicated in
634 interferon and inflammatory responses upon SARS-CoV-2 infection of ALI cultures retrieved
635 by GenGo Metacore.

636

637 **Supplementary Figure**

638 **Figure S1:** Mechanistic networks showing the interactions between upstream regulators
639 (*TNF*, *IL1A*, *F2*) and their target genes identified in the SARS-CoV-2 bulk RNA-seq
640 signature. The IPA upstream regulator analysis is based on the expected causal effects
641 between upstream regulators and targets.

642 **References**

- 643 1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-
644 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
645 Protease Inhibitor. *Cell*. 2020;181:271-280.e8.
- 646 2. Jevlev V, Mermerski K, Djakov L, Vassilev V. [Cases of mycoplasma abortion in swine].
647 *Zentralblatt Vet Reihe B J Vet Med Ser B*. 1972;19:588–97.
- 648 3. Bracquemond D, Muriaux D. Betacoronavirus Assembly: Clues and Perspectives for
649 Elucidating SARS-CoV-2 Particle Formation and Egress. *mBio*. 2021;12:e0237121.
- 650 4. Hiemstra PS, Tetley TD, Janes SM. Airway and alveolar epithelial cells in culture. *Eur*
651 *Respir J*. 2019;54:1900742.
- 652 5. Knabe L, Petit A, Vernisse C, Charriot J, Pugnère M, Henriquet C, et al. CCSP
653 counterbalances airway epithelial-driven neutrophilic chemotaxis. *Eur Respir J*.
654 2019;54:1802408.
- 655 6. Ahmed E, Fieldes M, Bourguignon C, Mianné J, Petit A, Jory M, et al. Differentiation of
656 Human Induced Pluripotent Stem Cells from Patients with Severe COPD into Functional
657 Airway Epithelium. *Cells*. 2022;11:2422.

- 658 7. Huang SXL, Islam MN, O'Neill J, Hu Z, Yang Y-G, Chen Y-W, et al. Efficient generation
659 of lung and airway epithelial cells from human pluripotent stem cells. *Nat Biotechnol.*
660 2014;32:84–91.
- 661 8. McCauley KB, Hawkins F, Serra M, Thomas DC, Jacob A, Kotton DN. Efficient
662 Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via
663 Temporal Regulation of Wnt Signaling. *Cell Stem Cell.* 2017;20:844-857.e6.
- 664 9. McCauley KB, Alysandratos K-D, Jacob A, Hawkins F, Caballero IS, Vedaie M, et al.
665 Single-Cell Transcriptomic Profiling of Pluripotent Stem Cell-Derived SCGB3A2+ Airway
666 Epithelium. *Stem Cell Rep.* 2018;10:1579–95.
- 667 10. Pezzulo AA, Starner TD, Scheetz TE, Traver GL, Tilley AE, Harvey B-G, et al. The air-
668 liquid interface and use of primary cell cultures are important to recapitulate the
669 transcriptional profile of in vivo airway epithelia. *Am J Physiol Lung Cell Mol Physiol.*
670 2011;300:L25-31.
- 671 11. Dvorak A, Tilley AE, Shaykhiev R, Wang R, Crystal RG. Do airway epithelium air-liquid
672 cultures represent the in vivo airway epithelium transcriptome? *Am J Respir Cell Mol Biol.*
673 2011;44:465–73.
- 674 12. Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface
675 TMPRSS2 to endosomal cathepsins for cell entry. *Virology.* 2018;517:9–15.
- 676 13. Djidrovski I, Georgiou M, Hughes GL, Patterson EI, Casas-Sanchez A, Pennington SH, et
677 al. SARS-CoV-2 infects an upper airway model derived from induced pluripotent stem cells.
678 *Stem Cells Dayt Ohio.* 2021;39:1310–21.
- 679 14. Abo KM, Ma L, Matte T, Huang J, Alysandratos KD, Werder RB, et al. Human iPSC-
680 derived alveolar and airway epithelial cells can be cultured at air-liquid interface and express
681 SARS-CoV-2 host factors. *BioRxiv Prepr Serv Biol.* 2020;2020.06.03.132639.
- 682 15. Vanderheiden A, Ralfs P, Chirkova T, Upadhyay AA, Zimmerman MG, Bedoya S, et al.
683 Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial
684 Cultures. *J Virol.* 2020;94:e00985-20.
- 685 16. Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos K-D, et al.
686 SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells
687 Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. *Cell Stem Cell.* 2020;27:962-
688 973.e7.
- 689 17. Osan JK, DeMontigny BA, Mehedi M. Immunohistochemistry for protein detection in
690 PFA-fixed paraffin-embedded SARS-CoV-2-infected COPD airway epithelium. *STAR*
691 *Protoc.* 2021;2:100663.
- 692 18. Ahmed E, Sansac C, Assou S, Gras D, Petit A, Vachier I, et al. Lung development,
693 regeneration and plasticity: From disease physiopathology to drug design using induced
694 pluripotent stem cells. *Pharmacol Ther.* 2018;183:58–77.
- 695 19. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-
696 2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;583:459–68.


- 697 20. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al.
698 Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*.
699 2020;181:1036-1045.e9.
- 700 21. Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, et al. COVID-
701 19: viral-host interactome analyzed by network based-approach model to study pathogenesis
702 of SARS-CoV-2 infection. *J Transl Med*. 2020;18:233.
- 703 22. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-CoV-2
704 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.
705 *EMBO J*. 2020;39:e105114.
- 706 23. Fiege JK, Thiede JM, Nanda HA, Matchett WE, Moore PJ, Montanari NR, et al. Single
707 cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in
708 primary human airway epithelium. *PLoS Pathog*. 2021;17:e1009292.
- 709 24. Vieira Braga FA, Kar G, Berg M, Carpaij OA, Polanski K, Simon LM, et al. A cellular
710 census of human lungs identifies novel cell states in health and in asthma. *Nat Med*.
711 2019;25:1153–63.
- 712 25. Ravindra NG, Alfajaro MM, Gasque V, Huston NC, Wan H, Szigeti-Buck K, et al.
713 Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium
714 identifies target cells, alterations in gene expression, and cell state changes. *PLoS Biol*.
715 2021;19:e3001143.
- 716 26. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient
717 cell states through dynamical modeling. *Nat Biotechnol*. 2020;38:1408–14.
- 718 27. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated
719 analysis of multimodal single-cell data. *Cell*. 2021;184:3573-3587.e29.
- 720 28. Cabello-Aguilar S, Alame M, Kon-Sun-Tack F, Fau C, Lacroix M, Colinge J.
721 SingleCellSignalR: inference of intercellular networks from single-cell transcriptomics.
722 *Nucleic Acids Res*. 2020;48:e55.
- 723 29. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
724 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill Bull Eur Sur Mal*
725 *Transm Eur Commun Dis Bull*. 2020;25:2000045.
- 726 30. Zhang Z, Zhu Z, Chen W, Cai Z, Xu B, Tan Z, et al. Cell membrane proteins with high N-
727 glycosylation, high expression and multiple interaction partners are preferred by mammalian
728 viruses as receptors. *Bioinforma Oxf Engl*. 2019;35:723–8.
- 729 31. Mason PR, Gwanzura L. Reduced lymphocyte responses to mitogens in natural and
730 experimental trichomoniasis. *Infect Immun*. 1990;58:3553–7.
- 731 32. Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ, et al. Respiratory syncytial virus
732 infection induces matrix metalloproteinase-9 expression in epithelial cells. *Arch Virol*.
733 2002;147:229–42.

- 734 33. Vermeer PD, Denker J, Estin M, Moninger TO, Keshavjee S, Karp P, et al. MMP9
735 modulates tight junction integrity and cell viability in human airway epithelia. *Am J Physiol*
736 *Lung Cell Mol Physiol*. 2009;296:L751-762.
- 737 34. Mecham RP, Broekelmann TJ, Fliszar CJ, Shapiro SD, Welgus HG, Senior RM. Elastin
738 degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of
739 elastolysis. *J Biol Chem*. 1997;272:18071-6.
- 740 35. Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, et al. A revised airway
741 epithelial hierarchy includes CFTR-expressing ionocytes. *Nature*. 2018;560:319-24.
- 742 36. Plasschaert LW, Žilionis R, Choo-Wing R, Savova V, Knehr J, Roma G, et al. A single-
743 cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. *Nature*.
744 2018;560:377-81.
- 745 37. Goldfarbmuren KC, Jackson ND, Sajuthi SP, Dyjack N, Li KS, Rios CL, et al. Dissecting
746 the cellular specificity of smoking effects and reconstructing lineages in the human airway
747 epithelium. *Nat Commun*. 2020;11:2485.
- 748 38. Barkauskas CE, Chung M-I, Fioret B, Gao X, Katsura H, Hogan BLM. Lung organoids:
749 current uses and future promise. *Dev Camb Engl*. 2017;144:986-97.
- 750 39. Miller AJ, Hill DR, Nagy MS, Aoki Y, Dye BR, Chin AM, et al. In Vitro Induction and
751 In Vivo Engraftment of Lung Bud Tip Progenitor Cells Derived from Human Pluripotent
752 Stem Cells. *Stem Cell Rep*. 2018;10:101-19.
- 753 40. Chen Y-W, Huang SX, de Carvalho ALRT, Ho S-H, Islam MN, Volpi S, et al. A three-
754 dimensional model of human lung development and disease from pluripotent stem cells. *Nat*
755 *Cell Biol*. 2017;19:542-9.
- 756 41. Huang SXL, Green MD, de Carvalho AT, Mumau M, Chen Y-W, D'Souza SL, et al. The
757 in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. *Nat*
758 *Protoc*. 2015;10:413-25.
- 759 42. Wohnhaas CT, Gindele JA, Kiechle T, Shen Y, Leparc GG, Stierstorfer B, et al. Cigarette
760 Smoke Specifically Affects Small Airway Epithelial Cell Populations and Triggers the
761 Expansion of Inflammatory and Squamous Differentiation Associated Basal Cells. *Int J Mol*
762 *Sci*. 2021;22:7646.
- 763 43. Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, et al. Morphogenesis and cytopathic
764 effect of SARS-CoV-2 infection in human airway epithelial cells. *Nat Commun*.
765 2020;11:3910.
- 766 44. Chien J-Y, Hsueh P-R, Cheng W-C, Yu C-J, Yang P-C. Temporal changes in
767 cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory
768 syndrome. *Respirol Carlton Vic*. 2006;11:715-22.
- 769 45. Melchjorsen J, Sørensen LN, Paludan SR. Expression and function of chemokines during
770 viral infections: from molecular mechanisms to in vivo function. *J Leukoc Biol*. 2003;74:331-
771 43.

- 772 46. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
773 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like
774 Disease. *Autoimmun Rev.* 2020;19:102537.
- 775 47. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence
776 and functions of the human interleukin (IL) gene family. *Hum Genomics.* 2010;5:30–55.
- 777 48. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol.*
778 2015;16:448–57.
- 779 49. McDermott JE, Mitchell HD, Gralinski LE, Einfeld AJ, Josset L, Bankhead A, et al. The
780 effect of inhibition of PP1 and TNF α signaling on pathogenesis of SARS coronavirus. *BMC*
781 *Syst Biol.* 2016;10:93.
- 782 50. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, et al. Immunophenotyping of
783 COVID-19 and influenza highlights the role of type I interferons in development of severe
784 COVID-19. *Sci Immunol.* 2020;5:eabd1554.
- 785 51. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate Immune
786 Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe.* 2020;27:883-
787 890.e2.
- 788 52. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master
789 regulator of type-I interferon-dependent immune responses. *Nature.* 2005;434:772–7.
- 790 53. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of
791 host defenses. *Annu Rev Immunol.* 2014;32:513–45.
- 792 54. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune
793 responses. *J Med Virol.* 2020;92:424–32.
- 794 55. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role
795 for antifibrotic therapy. *Lancet Respir Med.* 2020;8:807–15.
- 796 56. Ueland T, Holter JC, Holten AR, Müller KE, Lind A, Bekken GK, et al. Distinct and early
797 increase in circulating MMP-9 in COVID-19 patients with respiratory failure. *J Infect.*
798 2020;81:e41–3.
- 799 57. Hsu AT, Barrett CD, DeBusk GM, Ellson CD, Gautam S, Talmor DS, et al. Kinetics and
800 Role of Plasma Matrix Metalloproteinase-9 Expression in Acute Lung Injury and the Acute
801 Respiratory Distress Syndrome. *Shock Augusta Ga.* 2015;44:128–36.
- 802 58. Suprewicz Ł, Swoger M, Gupta S, Piktel E, Byfield FJ, Iwamoto DV, et al. Extracellular
803 vimentin as a target against SARS-CoV-2 host cell invasion. *BioRxiv Prepr Serv Biol.*
804 2021;2021.01.08.425793.
- 805 59. Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by
806 SARS-CoV-2. *Antiviral Res.* 2020;177:104759.
- 807 60. Trobaugh DW, Klimstra WB. MicroRNA Regulation of RNA Virus Replication and
808 Pathogenesis. *Trends Mol Med.* 2017;23:80–93.


- 809 61. Hanna J, Hossain GS, Kocerha J. The Potential for microRNA Therapeutics and Clinical
810 Research. *Front Genet.* 2019;10:478.
- 811 62. Zuo C, Sheng X, Liu Z, Ma M, Xiong S, Deng H, et al. MicroRNA-138 enhances TRAIL-
812 induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular
813 carcinoma cells. *Tumour Biol J Int Soc Oncodevelopmental Biol Med.*
814 2017;39:1010428317710410.
- 815 63. Chai W, Li J, Shangguan Q, Liu Q, Li X, Qi D, et al. Lnc-ISG20 Inhibits Influenza A
816 Virus Replication by Enhancing ISG20 Expression. *J Virol.* 2018;92:e00539-18.
- 817 64. Pichulik T, Khatamzas E, Liu X, Brain O, Delmiro Garcia M, Leslie A, et al. Pattern
818 recognition receptor mediated downregulation of microRNA-650 fine-tunes MxA expression
819 in dendritic cells infected with influenza A virus. *Eur J Immunol.* 2016;46:167–77.
- 820 65. Liang Y, Li E, Min J, Gong C, Gao J, Ai J, et al. miR-29a suppresses the growth and
821 metastasis of hepatocellular carcinoma through IFITM3. *Oncol Rep.* 2018;40:3261–72.
- 822 66. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB.
823 Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by
824 upregulating miR-130A. *J Virol.* 2012;86:10221–5.
- 825 67. Hart M, Walch-Rückheim B, Friedmann KS, Rheinheimer S, Tänzer T, Glombitza B, et
826 al. miR-34a: a new player in the regulation of T cell function by modulation of NF- κ B
827 signaling. *Cell Death Dis.* 2019;10:46.
- 828 68. Jia L-F, Wei S-B, Mitchelson K, Gao Y, Zheng Y-F, Meng Z, et al. miR-34a inhibits
829 migration and invasion of tongue squamous cell carcinoma via targeting MMP9 and MMP14.
830 *PloS One.* 2014;9:e108435.
- 831 69. Boufraquech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, et al. miR30a
832 inhibits LOX expression and anaplastic thyroid cancer progression. *Cancer Res.*
833 2015;75:367–77.
- 834 70. Seethy AA, Singh S, Mukherjee I, Pethusamy K, Purkayastha K, Sharma JB, et al.
835 Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions - An in-
836 silico study. *Placenta.* 2021;103:141–51.

837

Figure 1
A

B

| Epithelial Cell type | Marker | Model | | |
|----------------------|---------|------------------|-----|------|
| | | Biopsy -brushing | ALI | iALI |
| Secretory cells | SCGB1A1 | | | |
| Basal cells | TP63 | | | |
| Ciliated cells | FOXJ1 | | | |
| Ionocyte cells | FOXI1 | | | |
| Tuft cells | POU2F3 | | | |
| Neuroendocrine cells | ASCL1 | | | |

● Under-represented
● Overrepresented

C

D

| ssRNA virus | Receptor | Model | | |
|--------------------|----------|------------------|-----|------|
| | | Biopsy -brushing | ALI | iALI |
| SARS Coronavirus | ACE2 | | | |
| Rhino- Virus C | CDHR3 | | | |
| Coxsackie-Virus B1 | CD55 | | | |

Ciliated cells
 Secretory cells
 Basal cells
 Ionocyte cells

Figure 2




Figure 3






Figure 4

A




B



C

Relative expression



D








Figure 5**A****B****C****D**

Figure 6

